Dr. Heske headshot

Christine M. Heske, M.D.

  • Center for Cancer Research
  • National Cancer Institute


Dr. Heske is a physician-scientist with a laboratory and clinical research focus on novel therapeutic agents for pediatric sarcomas including rhabdomyosarcoma and Ewing sarcoma. Specifically, she seeks to identify and evaluate new therapeutic targets for these cancers by understanding the mechanisms behind therapeutic resistance and developing strategies to overcome such resistance through targeting tumor metabolism and DNA damage repair.

Areas of Expertise

DNA Damage and Repair
Early Phase Clinical Trials

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Recent Publications

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma

Gibson AE, Yeung C, Issaq SH, Collins VJ, Gouzoulis M, Zhang Y, Ji J, Mendoza A, Heske CM.
Oncogenesis. 9(9): 80, 2020. [ Journal Article ]

Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma

Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, Rai G, Urban DJ, Johnson MS, Benavides GA, Squadrito GL, Yohe ME, Lei H, Eldridge S, Hamre J 3rd, Dowdy T, Ruiz-Rodado V, Lita A, Mendoza A, Shern JF, Larion M, Helman LJ, Stott GM, Krishna MC, Hall MD, Darley-Usmar V, Neckers LM, Heske CM.
Cancer Res. 79(19): 5060-5073, 2019. [ Journal Article ]

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma

Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ.
Clin Cancer Res. 23(23): 7301-7311, 2017. [ Journal Article ]

The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma

Heske CM, Yeung C, Mendoza A, Baumgart JT, Edessa LD, Wan X, Helman LJ.
Transl Oncol. 9(6): 540-547, 2016. [ Journal Article ]

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma

Heske CM, Mendoza A, Edessa LD, Baumgart JT, Lee S, Trepel J, Proia DA, Neckers L, Helman LJ.
Oncotarget. 7(40): 65540-65552, 2016. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.


Learn more about CCR research advances, new discoveries and more on our news section.